Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL-13027 plus Gemcitabine and Nab-paclitaxel in Refractory Metastatic Pancreatic Cancer
NCT06199466Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of YL-13027 (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose and Recommended Phase 2 Dose at 1 year and Overall Response Rate at 1 year. Started Jan 2024; status: terminated.
02
Drugs
YL-13027
Beyond the preview
Go deeper on NCT06199466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06199466.